Search results for Net Pricing Drug Channel

The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)

This week, I’m rerunning some popular posts while we prepare for today’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Click here to see th...

Drug Channels News Roundup, Mid-April 2026: Vertical Integration & MLR Games, Copay Maximizers, Hospital Price Chaos...

I’m pleased to introduce a new recurring feature from Bryce Platt, DCI’s new Director. Each month, Bryce will highlight some of his most notable LinkedIn posts—for those of you who...

Protecting Gross-to-Net Performance Through Single-Channel Ecosystems

Today’s guest post comes from Peter Darch, SVP of Strategy and Operations at PHIL Inc. Peter explains that growing pressure on drug pricing is exposing structural inefficiencies i...

Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, an...

Spring has officially arrived at Drug Channels' worldwide headquarters in beautiful downtown Philadelphia. (Photo proof at right.) So, dive into this month’s curated crop of notewo...

Drug Channels News Roundup, Mid-May 2026: Flawed Launch Price Math, Rising Pharmacy Closures, Hospital Pay Realities, 34...

By Bryce Platt, PharmD The onslaught of pharmacy-related news doesn’t end. It may even be increasing in volume due to AI. But don’t worry—I’ve gathered some high-impact inf...

Informa Connect’s Life Sciences Pricing & Contracting USA

Informa Connect’s Life Sciences Pricing & Contracting USA May 18-20, 2026 | Philadelphia, PA Drug Channels readers save 10% with code 26DRCH10* Pricing & Contracting USA...

The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel (rerun)

This week, I’m rerunning some popular posts while we prepare for tomorrow’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. In February, I post...

List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Dr...

This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Since this article wa...

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain G...

By Adam J. Fein, Ph.D.Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs....

<![CDATA[More Than Just Pricing: MFN’s Impact on Pharma: Q&A with Lindsay Bealor Greenleaf]]>

Healthcare & Life Sciences: Drug Pricing Digest - April 2026 #2

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....By: Latham &...

<![CDATA[Asembia AXS26: The Battle for Drug Prices Ahead of the Midterms]]>

Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx’s Transparency, Must-Read 340B History, PBM Unbundling Update...

By Adam J. Fein, Ph.D.Summer unofficially kicked off last weekend. So fire up the grill and enjoy these noteworthy delicacies, seared to perfection on the Drug Channels barbeque:...

Are drug prices value-based?

One of the central tensions in pharmaceutical policy is the gap between what a drug is worth and what it actually costs. In theory, a drug’s price should reflect its value — its ab...

Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Upda...

It's time for Drug Channels Institute’s (DCI) annual update of vertical integration among insurers, PBMs, specialty pharmacies, and healthcare services within U.S. drug channels. A...

<![CDATA[The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation]]>

Healthcare & Life Sciences: Drug Pricing Digest - May 2026 #2

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....By: Latham &...

Healthcare & Life Sciences: Drug Pricing Digest - March 2026 #2

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....By: Latham &...

Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program

<![CDATA[Regeneron Agrees to Lower Drug Costs for U.S. Patients and Provide Otarmeni for Free]]>

<![CDATA[Asembia ASX26: The ‘Entirely Pass-Through’ Business Model]]>

The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (r...

This week, we're rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Click here to see...

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and...

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx. Laura suggests that manufacturers must move beyond payer-centric model...

Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point

The Drug Channels Institute (DCI) team attended Asembia’s AXS26 Summit last week. Once again, the specialty pharmacy market delivered a classic paradox: a sprawling, fragmented lan...